Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pneumococcal Vaccination in Adults.

Tsering Y Sherpa1, Howard L Leaf

  • 1Infectious Diseases Section, Veterans Affairs New York Harbor Healthcare System, 423 East 23rd Street, New York, NY 10010, USA. howard.leaf@med.va.gov.

Current Infectious Disease Reports
|April 26, 2005
PubMed
Summary

Pneumococcal vaccines, including the 23-valent and 7-valent conjugate types, are crucial for preventing community-acquired pneumonia and drug-resistant Streptococcus pneumoniae. Vaccination efforts are ongoing to improve coverage and develop more effective vaccines for at-risk populations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abnormal predicted diffusion capacities in healthy Asians: an inequality with a solution.

Respiration; international review of thoracic diseasesยท2006
See all related articles

Area of Science:

  • Infectious Diseases
  • Vaccinology
  • Public Health

Background:

  • Pneumococci are a leading cause of community-acquired pneumonia in adults, posing a significant mortality risk, especially in the elderly.
  • Increasing rates of drug-resistant Streptococcus pneumoniae necessitate enhanced disease prevention strategies, particularly vaccination.

Purpose of the Study:

  • To review the current landscape of pneumococcal vaccination in the United States.
  • To discuss the impact of existing vaccines and future directions in pneumococcal disease prevention.

Main Methods:

  • Review of existing literature on pneumococcal vaccines and disease epidemiology.
  • Analysis of vaccine efficacy and impact on disease incidence in different populations.

Main Results:

Related Experiment Videos

  • The 23-valent pneumococcal vaccine offers protection against bacteremic pneumococcal disease, particularly in immunocompetent individuals.
  • The 7-valent pneumococcal conjugate vaccine has significantly reduced pneumococcal disease in children and impacted incidence in unvaccinated adults.

Conclusions:

  • Vaccination remains a cornerstone in preventing pneumococcal pneumonia and combating antibiotic resistance.
  • Future efforts should focus on improving vaccination coverage in vulnerable groups and developing novel, more effective vaccines for high-risk individuals.